Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EXO-SKIN Epidermal is a regenerative biologic product developed by Regenesys, consisting of exosomes derived from mesenchymal stem cells (MSCs). These MSC-derived exosomes are extracellular vesicles that function as mediators of intercellular communication, transporting bioactive molecules such as proteins, lipids, and nucleic acids to recipient cells. The product is specifically designed for regenerative dermatology and skin repair, where it is intended to support epidermal healing and tissue regeneration by stimulating cellular proliferation and modulating the local microenvironment. As an exosome-based therapy, it offers a cell-free approach to regenerative medicine, potentially reducing the risks associated with direct stem cell transplantation while maintaining therapeutic efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EXO-SKIN Epidermal.